Combination Therapy for HIV Infection: Getting Closer

Editorials1 January 1992Combination Therapy for HIV Infection: Getting CloserAnthony S. Fauci, MDAnthony S. Fauci, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-116-1-85 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptPersons infected with the human immunodeficiency virus (HIV), their health care providers, and clinical investigators have recently expressed considerable interest in the possibility that combination therapy with antiretroviral agents might prove more beneficial than treatment with these agents used alone. The intensity of this interest has been heightened by the fact that zidovudine, which, until recently, was the only drug licensed for the treatment of HIV infection, has proved unsuccessful in completely suppressing virus replication (1) and in controlling disease progression over extended periods (2). In addition, virus isolates with diminished in-vitro sensitivity to zidovudine have emerged (3, 4) after...References1. HoMoudgilAlam DTM. Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. N Engl J Med. 1989;321:1621-5. CrossrefMedlineGoogle Scholar2. FischlRichmanCauseyGriecoBrysonMildvan MDDMYD. Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. AZT Collaborative Working Group. JAMA. 1989;262:2405-10. CrossrefMedlineGoogle Scholar3. LarderDarbyRichman BGD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science. 1989;243:1731-4. CrossrefMedlineGoogle Scholar4. RichmanGrimesLagakos DJS. Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus. J Acquir Immun Defic Syndr. 1990;3:743-6. MedlineGoogle Scholar5. Fauci A. The human immunodeficiency virus: infectivity and mechanisms of pathogenesis. Science. 1988;239:617-22. CrossrefMedlineGoogle Scholar6. MengFischlBootaSpectorBennettBassiakos TMASDY. Combination therapy with zidovudine and dideoxycytidine in patients with advanced HIV disease. A phase I/II study. Ann Intern Med. 1991;116:13-20. LinkGoogle Scholar7. Fauci A. ddI—a good start, but still phase I. N Engl J Med. 1990;322:1386-8. CrossrefMedlineGoogle Scholar8. LambertSeidlinReichmanPlankLavertyMorse JMRCMG. 2,3′-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. N Engl J Med. 1990;322:1333-40. CrossrefMedlineGoogle Scholar9. CooleyKunchesSaundersSaundersRitterPerkins TLCCJC. Once daily administration of 2′,3′-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. Results of a phase I trial. N Engl J Med. 1990;322:1340-5. CrossrefMedlineGoogle Scholar10. TornevikEriksson YS. 2′,3′-Dideoxycytidine toxicity in cultured human CEM T lymphoblasts: effects of combination with 3′-azido-3′deoxythymidine and thymidine. Mol Pharmacol. 1990;38:237-43. MedlineGoogle Scholar11. EronHirschMerrillChouJohnson JMDTV. Synergistic inhibition of HIV-1 by the combination of zidovudine (AZT) and 2′,3′-dideoxycytidine (ddC) in vitro. [Abstract]. Seventh International Conference on AIDS, Florence, Italy, 16-21 June 1991. Google Scholar12. St. ClairMartinTudor-WilliamsBachVavroKing MJGMCD. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science. 1991;253:1557-9. CrossrefMedlineGoogle Scholar13. KovacsDeytonDaveyFalloonZunichLee JLRJKD. Combined zidovudine and interferon-a therapy in patients with Kaposi sarcoma and acquired immunodeficiency syndrome (AIDS). Ann Intern Med. 1989;111:280-7. LinkGoogle Scholar14. KrownGoldNeidzwieckiBundowFlomenbergGansbacher SJDDNB. Interferon-alpha with zidovudine: safety, tolerance, and clinical and virologic effects in patients with Kaposi sarcoma associated with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med. 1990;112:812-21. LinkGoogle Scholar15. FischlUttamchandaniResnickAgarwalFletcherPatrone-Reese MRLRMJ. A phase I study of recombinant human interferon-alpha 2a or human lymphoblastoid interferon alpha nl and concomitant zidovudine in patients with AIDS-related Kaposi's sarcoma. J Acquir Immune Defic Syndr. 1991;4:1-10. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: National Institutes of Health Bethesda, MD 20892 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByIntervening on Conflict, Parental Bonds, and Sexual Risk Acts among Adolescent Children of Mothers Living with HIVRetinal Disease in HIV-infected PatientsSocial Support, Medication Compliance and HIV/AIDSGene TherapyPharmacokinetics of zidovudine and dideoxyinosine alone and in combination in children with HIV infection.Combination Antiretroviral Therapy for HIV InfectionChapter 14. HIV Protease InhibitorsA Study of the Safety and Survival of the Adoptive Transfer of Genetically Marked Syngeneic Lymphocytes in HIV-infected Identical TwinsZidovudine: Five Years LaterGavin X. McLeod, MD, Scott M. Hammer, MDTreatment of HIV infection in infants and childrenThe Pharmacological Treatment of Human Immunodeficiency Virus Infection 1 January 1992Volume 116, Issue 1Page: 85-86KeywordsAllergy and immunologyAntiretroviral therapyAntiretroviralsDrugsHIVHIV infectionsHealth care providersInfectious diseases Issue Published: 1 January 1992 PDF DownloadLoading ...